DarioHealth to Host Investor Conference Call on October 4, 2018

    Call to review recent fundraise, expected accelerated growth, and introduce new President and new Chairman

    Sep 20, 2018

    CAESAREA, Israel, Sept. 20, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will host a conference call to provide a business update for investors at 9:00am EDT on Thursday, October 4, 2018. The conference call will be hosted by Erez Raphael, Chief Executive Officer, Olivier Jarry, President and Chief Commercial Officer, Zvi Ben-David, Chief Financial Officer, and Yoav Shaked, Chairman of the Board. The live conference call can be accessed by dialing 877-407-8035 or 201-689-8035 (international). Participants should ask for the DarioHealth Investor Update Conference Call. The conference call will also be available via live webcast at: http://www.investorcalendar.com/event/37592

    Dario Health (PRNewsfoto/DarioHealth Corp.)

    Conference Call Details:
    Date: Thursday, October 4, 2018
    Time: 9:00am EDT
    Dial-in Number: 877-407-8035
    International Dial-in Number: 201-689-8035

    Webcast http://www.investorcalendar.com/event/37592

    Participants are recommended to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through October 18, 2018. To listen to the replay, dial 877-481-4010 (domestic) or 919-882-2331 (international) and use replay passcode 37592. The webcast replay will be available through January 4, 2019.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes it's expected accelerated growth, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing, joao@mydario.com, 1-914-775-5548

     

    SOURCE DarioHealth Corp.


    print email rss